$TEVA News
Last published 1d ago
- 1d agoTEVATeva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030GlobeNewswireTeva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma.
- 1w agoTEVATEVA PHARMACEUTICAL INDUSTRIES LTD - PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoTEVATeva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin ExpansionGlobeNewswireCOMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION OF BXCL-501 Q3 2026 revenues of $4.4 billion, a decrease of 2% year-over-year in both U.S. dollars and local currency terms,
- 1w agoTEVATeva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.GlobeNewswireTeva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027Collaboration combines Samsung Bioepis’ biosimilar expertise with Teva’s commercial
- 1w agoTEVATeva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility AnalysisGlobeNewswirePredictive Interim analysis indicates low probability of study meeting its primary efficacy endpoint if continuedComprehensive analysis and evaluation of available open-label extension data will followNo safety concerns
- 2w agoTEVATeva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience PipelineGlobeNewswireBXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adultsAcquisition adds
- 3w agoTEVAUEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s DiseaseGlobeNewswireIn UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical
- 1mo agoTEVATeva to Host R&D Day on Wednesday, November 11 in New York CityGlobeNewswireTEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day,
- 1mo agoTEVAWELTRUZA™ (olanzapine) Approval – Conference Call - TEVA PHARMACEUTICAL INDUSTRIES LTDEarnings Call TranscriptsHello and welcome to the Welltrusa Approval Conference Call. My name is Alex and I'll be coordinating today's call. If you'd like to ask a question during the presentation, please press star followed by one on your telep
- 1mo agoTEVATeva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with SchizophreniaGlobeNewswireWELTRUZA™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with
- 1mo agoTEVAApproval of Degevma, Bla #761481FDA Approved DrugsApproval Date: 09/25/2026; Drug Name: Degevma, Bla #761481; Active Ingredients: DENOSUMAB-ADET; Company: Teva Pharmaceuticals, Inc.; Submission Status: Approval; Application Number: 761481
- 1mo agoTEVANew Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older PatientsGlobeNewswireNew data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tardive dyskinesia
- 1mo agoTEVATeva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare CostsGlobeNewswireNew findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I)The new real-world data also show that
- 1mo agoTEVATeva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in AdultsGlobeNewswireIn a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of participants
- 1mo agoTEVATeva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia CareGlobeNewswireLong-acting injectables (LAIs) offer an opportunity to improve adherence and potential outcomes for patients with schizophreniaLongActingImpact.com is a new resource center designed to support clinicians in having
- 1mo agoTEVAMorgan Stanley 24th Annual Global Healthcare Conference - TEVA PHARMACEUTICAL INDUSTRIES LTDEarnings Call TranscriptsOkay, perfect. So, good morning, everyone. Thank you for joining this session of the Morgan Stanley Global Healthcare Conference. For those of you who don't know me, I'm Sarita Kapila, European Pharma Research Analyst he
- 1mo agoTEVATeva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth StrategyGlobeNewswirePARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ordinary shares will
- 2mo agoTEVATeva Announces Successful Pricing of $4.9 billion (Equivalent) Senior NotesGlobeNewswireTEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully priced its offering of approximately $4.9 billion
- 2mo agoTEVATeva Announces Launch of Offering of Senior NotesGlobeNewswireTEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today its intention to issue senior notes through its special purpose finance
- 2mo agoTEVAS&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial DisciplineGlobeNewswireTEL AVIV, Israel, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer
- 2mo agoTEVAIL-15 Celiac Disease Phase 2a Topline Results - Conference Call - TEVA PHARMACEUTICAL INDUSTRIES LTDEarnings Call TranscriptsHello everyone and thank you for joining us today for the IL-15 CDAC disease phase 2a top-line results conference call. My name is Sammy and I'll be coordinating your call today. During the presentation you can register
- 2mo agoTEVATeva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product PotentialGlobeNewswireTeva-discovered TEV ‘408, a novel anti-IL-15 monoclonal antibody, demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage vs placebo following a single
- 2mo agoTEVATeva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in SeptemberGlobeNewswireTEL AVIV, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at three upcoming
- 2mo agoTEVATeva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.GlobeNewswirePARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with
- 2mo agoTEVAANDTeva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth StrategyGlobeNewswireBXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder
- 2mo agoTEVAU.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette SyndromeGlobeNewswireEcopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designationNDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b
- 3mo agoTEVAMoody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth StrategyGlobeNewswireTEL AVIV, Israel, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Moody’s Ratings has upgraded Teva’s corporate credit rating to Baa3 from Ba1, an
- 3mo agoTEVAApproval of Glyburide And Metformin Hydrochloride, Anda #076821 (Labeling)FDA Approved DrugsApproval Date: 08/11/2026; Drug Name: Glyburide And Metformin Hydrochloride, Anda #076821; Active Ingredients: GLYBURIDE; METFORMIN HYDROCHLORIDE; Company: Teva; Submission Status: Approval; Submission Classification: Labeling; Application Number: 076821
- 3mo agoTEVAApproval of Metformin Hydrochloride, Anda #076864 (Labeling)FDA Approved DrugsApproval Date: 08/11/2026; Drug Name: Metformin Hydrochloride, Anda #076864; Active Ingredients: METFORMIN HYDROCHLORIDE; Company: Teva; Submission Status: Approval; Submission Classification: Labeling; Application Number: 076864
- 3mo agoTEVAApproval of Metformin Hydrochloride, Anda #076269 (Labeling)FDA Approved DrugsApproval Date: 08/11/2026; Drug Name: Metformin Hydrochloride, Anda #076269; Active Ingredients: METFORMIN HYDROCHLORIDE; Company: Teva; Submission Status: Approval; Submission Classification: Labeling; Application Number: 076269
- 3mo agoTEVATeva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth StrategyGlobeNewswireQ2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues. Our key innovative brands collectively grew 43% YoY in
- 3mo agoSDZ-CHHIK-GBHIK-AEFME-DE+5Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supplyCNBCTrump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear.
- 4mo agoTEVAANDTeva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple SclerosisBusiness WireTeva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot
- 4mo agoTEVAANDTeva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple SclerosisGlobeNewswireTeva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to
- 4mo agoTEVAIL-15 Vitiligo Phase 1b 24 Week Efficacy Results - Conference Call - Teva Pharmaceutical Industries Ltd.Earnings Call TranscriptsHello and welcome to the IL15 Vitiligo Phase 1B 24-Week Efficacy Results Conference Call. My name is Alex and I'll be coordinating today's call. If you'd like to ask a question at the end of the presentation, please pres
- 4mo agoTEVATeva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b ResultsGlobeNewswireTeva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to dateNearly 75% of patients reported
- 4mo agoTEVAApproval of Finasteride, Anda #076511 (Labeling)FDA Approved DrugsApproval Date: 07/02/2026; Drug Name: Finasteride, Anda #076511; Active Ingredients: FINASTERIDE; Company: Teva; Submission Status: Approval; Submission Classification: Labeling; Application Number: 076511
- 4mo agoTEVATeva Releases Q2 2026 Aide MemoireGlobeNewswireTEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the "Investors" page on its website. Q2 2026
- 4mo agoTEVATeva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette SyndromeGlobeNewswireNDA submission supported by positive Phase 3 data recently published in JAMA Neurology.Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan
- 4mo agoTEVATeva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ETGlobeNewswireTEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial
- 4mo agoTEVAApproval of Tramadol Hydrochloride, Anda #075977 (REMS)FDA Approved DrugsApproval Date: 06/18/2026; Drug Name: Tramadol Hydrochloride, Anda #075977; Active Ingredients: TRAMADOL HYDROCHLORIDE; Company: Teva; Submission Status: Approval; Submission Classification: REMS; Application Number: 075977
- 4mo agoTEVAApproval of Oxymorphone Hydrochloride, Anda #091443 (REMS)FDA Approved DrugsApproval Date: 06/18/2026; Drug Name: Oxymorphone Hydrochloride, Anda #091443; Active Ingredients: OXYMORPHONE HYDROCHLORIDE; Company: Teva; Submission Status: Approval; Submission Classification: REMS; Application Number: 091443
- 5mo agoTEVATeva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth StrategyGlobeNewswireEcopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track
- 5mo agoTEVATeva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and CareGlobeNewswireNew analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led to reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all participants, which were associated with
- 5mo agoTEVAGoldman Sachs 47th Annual Global Healthcare Conference - Teva PharmaceuticalsEarnings Call TranscriptsOkay, great, great. Well, good morning, everyone, and thank you for joining us. My name is Matt DeLaTorre, and I'm a biopharma analyst here at Goldman Sachs, and we're really excited to kick off the conference this morni
- 5mo agoTEVATeva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease ChoreaGlobeNewswireNew real-world survey data reveal the daily impact of Huntington's disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of caregivers noting impact
- 5mo agoTEVATentative Approval of Trilaciclib, Anda #219413FDA Approved DrugsApproval Date: 06/05/2026; Drug Name: Trilaciclib, Anda #219413; Active Ingredients: TRILACICLIB; Company: Teva Pharmaceuticals, Inc.; Submission Status: Tentative Approval; Application Number: 219413
- 5mo agoTEVATeva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®GlobeNewswireAHZANTIVE® (aflibercept) is an EMA-approved biosimilar to Eylea® (aflibercept) with demonstrated similarity in efficacy, safety and immunogenicity to the reference product The launch expands Teva's biosimilars
- 5mo agoTEVATeva to Present at the Goldman Sachs Global Healthcare ConferenceGlobeNewswirePARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate
- 5mo agoTEVAANDThe European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-'749) for the Treatment of Schizophrenia in AdultsGlobeNewswireThe olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a significant unmet